SAN FRANCISCO -- More adults with moderate-to-severe Crohn's disease (CD) reached clinical remission after 6 months on ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

Invest in essential sectors like consumer staples and energy to beat inflation. See why these stocks offer reliable dividends ...

ABBV stock, with 24% returns since the beginning of 2024, has marginally underperformed the S&P 500 index, up 27%. An ...

Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.

Artificial intelligence (AI) is transforming various industries as a major investing theme in 2025. The technology's ability ...

AbbVie Inc . (NYSE:ABBV), currently trading at $190.14, has demonstrated resilience and strategic foresight as it navigates the loss of exclusivity for its blockbuster drug Humira. The ...

Global oncology portfolio sales were $1.7 billion, up 12%. Imbruvica sales were $848 million, down 6%. Venclexta sales were $655 million, up 11%. Elahere revenues were $148 million.

A Maryland mom got diagnosed with a condition she didn’t know she had. Then she couldn’t afford the medicine. Now, state ...

Tariffs and price inflation for specialty medications will increase costs, according to research from Vizient.

Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...